AVEO Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan 04, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011 at 10:00 a.m. (PST) at the Westin St. Francis Hotel in San Francisco. Mr. Ha-Ngoc is expected to present an overview of the company and updated financial guidance.
A live webcast of AVEO's presentation can be accessed by visiting the investors section of the company's website at investor.aveopharma.com. A replay of the webcast will be archived on the AVEO website for two weeks following the presentation.
AVEO Pharmaceuticals (NASDAQ: AVEO) is a cancer therapeutics company committed to discovering, developing and commercializing targeted therapies to impact patients' lives. The company's lead product candidate, tivozanib, is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in patients with advanced renal cell carcinoma, as well as additional clinical studies in other solid tumor types. AVEO's second most advanced product candidate, AV-299, is a potent, functional anti-HGF/c-MET pathway antibody that is currently in Phase 2 clinical development. AVEO's proprietary Human Response Platform(TM) offers the company a unique advantage in cancer drug development and has provided a discovery engine for high-value therapeutic targets. This approach has resulted in a promising pipeline of monoclonal antibodies against novel targets including HGF, ErbB3, RON, Notch and FGFR. For more information, please visit the company's website at www.aveopharma.com.
SOURCE: AVEO Pharmaceuticals, Inc.
AVEO Pharmaceuticals, Inc.
Monique Allaire, 617-299-5810
Caton Lovett, 910-232-7166